Agmatine, the natural metabolite of the amino acid arginine, has previously been reported to support nerve health (Pain Medicine, 2010, Vol. 11, pp. 356-368), and the new patent (#9,585,852) is a “very significant and important landmark achievement for Gilad&Gilad”, said the company.
The new patent broadens the patented use of agmatine beyond just neuroprotection (as described in US patent # 8,916,612) to general cytoprotection, ie, protect many other cell types.
“Maintenance of normal nerve cell activities critically relies on the support of a variety of other cell types (e.g., vascular, muscular, connective and immune cells). In other words, proper nervous system functions depend on the concerted interactions of many cell types,” said Dr Gad Gilad, CEO of Gilad&Gilad.
“Agmatine with its postulated molecular shotgun-like mechanism of action is so unique, because as a single dietary ingredient it provides broad cytoprotection by modulating, potentially synergistically, multiple molecular mechanisms which underlie the cell's own molecular stress response. Consequently, by exerting general cytoprotection, agmatine provides not only for vigorous the nervous system functions, but also for vitality of other bodily tissues, and that without unwanted side effects.”
No clinical studies to support bodybuilding
Dr Gilad added that there are no clinical studies to back any indications beyond nerve health.
“That agmatine is touted for bodybuilding, is completely unsubstantiated and is misleading as it is backed by outright false claims,” he said.